Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Merck & Co., Inc. (MRK) – Merck & Co., Inc. Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Merck (MRK) trades at $112.37, up 0.96% with neutral technical signals. The company reported strong Q3 and Q4 2025 earnings beats and maintains robust profitability with 73.91% gross margins and 13.59% net income margin. Recent news highlights Merck's $6.7 billion acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth investments amid competitive pressures.
Wall Street consensus remains bullish with 67.57% buy ratings and a $138.67 price target, suggesting 23% upside. Key risks include patent expirations, regulatory scrutiny, and integration challenges from recent acquisitions. The stock's valuation at 31.96 P/E appears elevated but justified by strong cash flow generation and strategic pipeline expansion.
Read full analysis

Key Stats

  • Market Cap
    $280.20B
  • Sector
    Health
  • 3M Drawdown
    -11.93%
  • Enterprise Value
    $323.62B
  • Dividend Yield
    3%
  • Trading Activity
    55% Buy | 45% Sell
  • Typical Hold Time
    98 days
$113.5
52W Low: $73.47
14 May 2025
52W High: $123.93
24 Feb 2026

Merck & Co., Inc. (MRK) is currently valued at a market capitalization of $280.20B, with an enterprise value of $323.62B. Over the past 52 weeks, Merck & Co., Inc. has traded between a low of $73.47 and a high of $123.93, highlighting its annual price range. Over the past three months, Merck & Co., Inc. has recorded a drawdown of -11.93%, reflecting recent price volatility. Merck & Co., Inc. offers a dividend yield of 3%, with the most recent dividend of $0.85 paid on 16 Mar 26. On average, investors hold Merck & Co., Inc. for approximately 98 days, indicating typical investor behavior on the platform.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.


Technical Indicators
|
|
|
Overall Summary
Bearish (10)Neutral (5)Bullish (12)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $280.20B
  • Sector
    Health
  • 3M Drawdown
    -11.93%
  • Enterprise Value
    $323.62B
  • Dividend Yield
    3%
  • Trading Activity
    55% Buy | 45% Sell
  • Typical Hold Time
    98 days
$113.5
52W Low: $73.47
14 May 2025
52W High: $123.93
24 Feb 2026

Merck & Co., Inc. (MRK) is currently valued at a market capitalization of $280.20B, with an enterprise value of $323.62B. Over the past 52 weeks, Merck & Co., Inc. has traded between a low of $73.47 and a high of $123.93, highlighting its annual price range. Over the past three months, Merck & Co., Inc. has recorded a drawdown of -11.93%, reflecting recent price volatility. Merck & Co., Inc. offers a dividend yield of 3%, with the most recent dividend of $0.85 paid on 16 Mar 26. On average, investors hold Merck & Co., Inc. for approximately 98 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!